Skip to content

Study · Randomized controlled trial · 1999

4 results

Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.

Pazos F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C

Fertility and sterility1 Jan 1999Cited by 26 (Europe PMC)

PMID9935128 (opens in a new tab)DOI10.1016/s0015-0282(98)00414-2 (opens in a new tab)PepBankPUB-09935128
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hirsute women, scores after triptorelin were higher than after flutamide at 9 months, with oral contraception in both groups.

    In plain wordsIn hirsute women, scores were higher with triptorelin than flutamide at 9 months, with oral contraception in both groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseHirsutism score versus flutamide
    Study

    n: not reported in source

    Comparator
    Flutamide with oral contraceptive
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    3.75 mg every 28 days · intramuscular · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    This decrease was more pronounced after 9 months of treatment, especially in the patients who received flutamide, who had lower hirsutism scores compared with the other treatment groups.
    2 context sentences
    Summary · context
    Patients were randomly assigned to receive triptorelin (3.75 mg IM every 28 days), CPA (100 mg/d orally on days 1-10 of the menstrual cycle), or flutamide (250 mg orally twice daily).
    Summary · context
    All the patients also received a triphasic oral contraceptive.
  2. 02HumanRandomized controlled trialSafety outcome

    In hirsute women, serum lipids increased mildly, mostly in the triptorelin group receiving background oral contraception.

    In plain wordsIn hirsute women, blood fats increased mildly, mostly with triptorelin and background oral contraception.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSerum lipid concentrations
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    3.75 mg every 28 days · intramuscular · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a mild increase in serum lipid concentrations, mostly in the group treated with triptorelin.
    3 context sentences
    Summary · context
    Thirty-nine hirsute women with idiopathic or functional ovarian hyperandrogenism.
    Summary · context
    Patients were randomly assigned to receive triptorelin (3.75 mg IM every 28 days), CPA (100 mg/d orally on days 1-10 of the menstrual cycle), or flutamide (250 mg orally twice daily).
    Summary · context
    All the patients also received a triphasic oral contraceptive.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In hirsute women, hirsutism scores decreased in all groups, including triptorelin with background oral contraception.

    In plain wordsIn women with hirsutism, scores decreased in all groups, including triptorelin with oral contraception.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseHirsutism score change
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    The Ferriman-Gallwey score decreased in all the groups.
    3 context sentences
    Summary · context
    Thirty-nine hirsute women with idiopathic or functional ovarian hyperandrogenism.
    Summary · context
    Patients were randomly assigned to receive triptorelin (3.75 mg IM every 28 days), CPA (100 mg/d orally on days 1-10 of the menstrual cycle), or flutamide (250 mg orally twice daily).
    Summary · context
    All the patients also received a triphasic oral contraceptive.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In hirsute women, no patients had abnormal liver tests, including those receiving triptorelin with oral contraception.

    In plain wordsIn hirsute women, liver tests remained normal in all groups, including triptorelin with oral contraception.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeAbnormal liver function tests
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    None of the patients had abnormal liver function test results.
    3 context sentences
    Summary · context
    Thirty-nine hirsute women with idiopathic or functional ovarian hyperandrogenism.
    Summary · context
    Patients were randomly assigned to receive triptorelin (3.75 mg IM every 28 days), CPA (100 mg/d orally on days 1-10 of the menstrual cycle), or flutamide (250 mg orally twice daily).
    Summary · context
    All the patients also received a triphasic oral contraceptive.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.